MRI-Guided treatment reduction for stage 2-3 triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests if using MRI scans can safely reduce the amount of chemotherapy and immunotherapy needed before surgery for triple-negative breast cancer. All patients will receive the standard KEYNOTE-522 regimen, but the treatment may be tailored based on MRI results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 2 or 3 triple-negative breast cancer (tumor markers ER, PR, and HER2 are all negative).
- You are healthy enough to receive the standard KEYNOTE-522 chemotherapy and immunotherapy combination.
- You have not had an excisional biopsy (removing the whole tumor) or lymph node removal on that side before starting treatment.
- You have no evidence that the cancer has spread to distant organs (stage 4).
- You are 18 or older and have adequate bone marrow, liver, kidney, and heart function.
- You agree to use effective birth control if you or your partner could become pregnant, for at least 6 months after the last dose of pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
This trial tests whether using blood tests and imaging during chemotherapy and immunotherapy can help guide treatment for early-stage triple-negative breast cancer. It aims to improve outcomes by adjusting treatment based on how the cancer responds.
This trial is testing whether a shorter course of chemo plus an immunotherapy drug called pembrolizumab works as well as the standard longer treatment for early-stage triple-negative breast cancer. The goal is to reduce side effects while keeping the treatment effective.
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.